The impact of syndromic treatment of sexually transmitted diseases on genital shedding of HIV-1.

OBJECTIVES: To examine the impact of sexually transmitted diseases (STD) syndromic treatment on genital shedding of HIV and the impact among women in whom STD treatment was not successful. DESIGN: Seventy-one HIV-infected women were included; 60 had symptomatic STD [72% with genital discharge syndr...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй
Үндсэн зохиолчид: Wolday, D, Gebremariam, Z, Mohammed, Z, Dorigo-Zetsma, W, Meles, H, Messele, T, Geyid, A, Sanders, E, Maayan, S
Формат: Journal article
Хэл сонгох:English
Хэвлэсэн: 2004
_version_ 1826307038039244800
author Wolday, D
Gebremariam, Z
Mohammed, Z
Dorigo-Zetsma, W
Meles, H
Messele, T
Geyid, A
Sanders, E
Maayan, S
author_facet Wolday, D
Gebremariam, Z
Mohammed, Z
Dorigo-Zetsma, W
Meles, H
Messele, T
Geyid, A
Sanders, E
Maayan, S
author_sort Wolday, D
collection OXFORD
description OBJECTIVES: To examine the impact of sexually transmitted diseases (STD) syndromic treatment on genital shedding of HIV and the impact among women in whom STD treatment was not successful. DESIGN: Seventy-one HIV-infected women were included; 60 had symptomatic STD [72% with genital discharge syndrome (GDS) and 28% with genital ulcer syndrome (GUS)] and 11 controls did not have symptomatic STD. Cervical HIV load in 94% women was measured at baseline and after STD treatment. RESULTS: Cervical HIV load at entry was significantly higher in women with symptomatic STD than in controls [median, 3.15; interquartile range (IQR), 1.90-3.34 versus median, 1.90; IQR, 1.90-2.19 log10 RNA copies/swab, respectively; P = 0.024]. Women with STD were also more likely to have detectable cervical HIV RNA (68% versus 27%; P = 0.016). Cervical HIV load was significantly higher in women with GUS than in those with GDS (median 3.46; IQR, 2.84-4.18 versus median, 2.83; IQR, 1.90-3.31 log10 copies/swab; P = 0.019). There was no significant reduction in genital HIV shedding after syndromic treatment of GDS or GUS. However, significant decreases were limited to only those with clinical improvement (median, 2.91; IQR, 1.90-3.45 versus median, 2.25; IQR, 1.90-3.08 log10 RNA copies/swab, respectively; P = 0.006). GUS was significantly associated with treatment failure, independent of plasma HIV RNA load and CD4 T-cell count (odds ratio, 4.79; 95% confidence interval, 1.32-17.46). CONCLUSIONS: The fact that STD syndromic treatment impacts very little in reducing genital HIV shedding underscores the need for appropriate validation of STD syndromic diagnosis and management to control heterosexual transmission of HIV.
first_indexed 2024-03-07T06:57:00Z
format Journal article
id oxford-uuid:fe76bccc-722b-443a-8bb7-e47480452bff
institution University of Oxford
language English
last_indexed 2024-03-07T06:57:00Z
publishDate 2004
record_format dspace
spelling oxford-uuid:fe76bccc-722b-443a-8bb7-e47480452bff2022-03-27T13:36:44ZThe impact of syndromic treatment of sexually transmitted diseases on genital shedding of HIV-1.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:fe76bccc-722b-443a-8bb7-e47480452bffEnglishSymplectic Elements at Oxford2004Wolday, DGebremariam, ZMohammed, ZDorigo-Zetsma, WMeles, HMessele, TGeyid, ASanders, EMaayan, S OBJECTIVES: To examine the impact of sexually transmitted diseases (STD) syndromic treatment on genital shedding of HIV and the impact among women in whom STD treatment was not successful. DESIGN: Seventy-one HIV-infected women were included; 60 had symptomatic STD [72% with genital discharge syndrome (GDS) and 28% with genital ulcer syndrome (GUS)] and 11 controls did not have symptomatic STD. Cervical HIV load in 94% women was measured at baseline and after STD treatment. RESULTS: Cervical HIV load at entry was significantly higher in women with symptomatic STD than in controls [median, 3.15; interquartile range (IQR), 1.90-3.34 versus median, 1.90; IQR, 1.90-2.19 log10 RNA copies/swab, respectively; P = 0.024]. Women with STD were also more likely to have detectable cervical HIV RNA (68% versus 27%; P = 0.016). Cervical HIV load was significantly higher in women with GUS than in those with GDS (median 3.46; IQR, 2.84-4.18 versus median, 2.83; IQR, 1.90-3.31 log10 copies/swab; P = 0.019). There was no significant reduction in genital HIV shedding after syndromic treatment of GDS or GUS. However, significant decreases were limited to only those with clinical improvement (median, 2.91; IQR, 1.90-3.45 versus median, 2.25; IQR, 1.90-3.08 log10 RNA copies/swab, respectively; P = 0.006). GUS was significantly associated with treatment failure, independent of plasma HIV RNA load and CD4 T-cell count (odds ratio, 4.79; 95% confidence interval, 1.32-17.46). CONCLUSIONS: The fact that STD syndromic treatment impacts very little in reducing genital HIV shedding underscores the need for appropriate validation of STD syndromic diagnosis and management to control heterosexual transmission of HIV.
spellingShingle Wolday, D
Gebremariam, Z
Mohammed, Z
Dorigo-Zetsma, W
Meles, H
Messele, T
Geyid, A
Sanders, E
Maayan, S
The impact of syndromic treatment of sexually transmitted diseases on genital shedding of HIV-1.
title The impact of syndromic treatment of sexually transmitted diseases on genital shedding of HIV-1.
title_full The impact of syndromic treatment of sexually transmitted diseases on genital shedding of HIV-1.
title_fullStr The impact of syndromic treatment of sexually transmitted diseases on genital shedding of HIV-1.
title_full_unstemmed The impact of syndromic treatment of sexually transmitted diseases on genital shedding of HIV-1.
title_short The impact of syndromic treatment of sexually transmitted diseases on genital shedding of HIV-1.
title_sort impact of syndromic treatment of sexually transmitted diseases on genital shedding of hiv 1
work_keys_str_mv AT woldayd theimpactofsyndromictreatmentofsexuallytransmitteddiseasesongenitalsheddingofhiv1
AT gebremariamz theimpactofsyndromictreatmentofsexuallytransmitteddiseasesongenitalsheddingofhiv1
AT mohammedz theimpactofsyndromictreatmentofsexuallytransmitteddiseasesongenitalsheddingofhiv1
AT dorigozetsmaw theimpactofsyndromictreatmentofsexuallytransmitteddiseasesongenitalsheddingofhiv1
AT melesh theimpactofsyndromictreatmentofsexuallytransmitteddiseasesongenitalsheddingofhiv1
AT messelet theimpactofsyndromictreatmentofsexuallytransmitteddiseasesongenitalsheddingofhiv1
AT geyida theimpactofsyndromictreatmentofsexuallytransmitteddiseasesongenitalsheddingofhiv1
AT sanderse theimpactofsyndromictreatmentofsexuallytransmitteddiseasesongenitalsheddingofhiv1
AT maayans theimpactofsyndromictreatmentofsexuallytransmitteddiseasesongenitalsheddingofhiv1
AT woldayd impactofsyndromictreatmentofsexuallytransmitteddiseasesongenitalsheddingofhiv1
AT gebremariamz impactofsyndromictreatmentofsexuallytransmitteddiseasesongenitalsheddingofhiv1
AT mohammedz impactofsyndromictreatmentofsexuallytransmitteddiseasesongenitalsheddingofhiv1
AT dorigozetsmaw impactofsyndromictreatmentofsexuallytransmitteddiseasesongenitalsheddingofhiv1
AT melesh impactofsyndromictreatmentofsexuallytransmitteddiseasesongenitalsheddingofhiv1
AT messelet impactofsyndromictreatmentofsexuallytransmitteddiseasesongenitalsheddingofhiv1
AT geyida impactofsyndromictreatmentofsexuallytransmitteddiseasesongenitalsheddingofhiv1
AT sanderse impactofsyndromictreatmentofsexuallytransmitteddiseasesongenitalsheddingofhiv1
AT maayans impactofsyndromictreatmentofsexuallytransmitteddiseasesongenitalsheddingofhiv1